Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 39

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 39
---
 share in all dividends that our Board of Directors, in its discretion, declares from legally available funds. In the event
of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain
after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The common
stock has no pre-emptive, subscription or conversion rights and there are no redemption provisions applicable to the common stock.

Preferred Stock

We are authorized to issue up to 10,000,000 shares
of preferred stock, par value $0.001 per share, from time to time in one or more series. On December 30, 2020, we filed a Certificate
of Designation of Series A Junior Preferred Stock with the Secretary of State of the State of Delaware to designate 45,000 shares as Series
A Preferred Junior Participating Preferred Stock. As of the date of this prospectus, there were no shares of our preferred stock outstanding.

Our articles of incorporation authorizes our Board
of Directors to issue preferred stock from time to time with such designations, preferences, conversion or other rights, voting powers,
restrictions, dividends or limitations as to dividends or other distributions, qualifications or terms or conditions of redemption as
shall be determined by the Board of Directors for each class or series of stock. Preferred stock is available for possible future financings
or acquisitions and for general corporate purposes without further authorization of stockholders unless such authorization is required
by applicable law, the rules of Nasdaq or other securities exchange or market on which our stock is then listed or admitted to trading.

<div align='center'>7</div>

Our Board of Directors may authorize the issuance
of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common
stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes
could, under some circumstances, have the effect of delaying, deferring or preventing a change-in-control of the Company.

A prospectus supplement relating to any series
of preferred stock being offered will include specific terms relating to the offering. Such prospectus supplement will include:

| ● | the                                                   
 title and stated or par value of the preferred stock; |

| ● | the                                                                                                                                  
 number of shares of the preferred stock offered, the liquidation preference per share and the offering price of the preferred stock; |

| ● | the